Xenogrow (Minoxidil)

Therapeutic Group: Skin Hair Growth Promoter

Xenogrow topical solultion 2%: Each mL solution contains Minoxidil USP 20 mg Xenogrow topical solultion 5%: Each mL solution contains Minoxidil USP 50 mg

Minoxidil is a peripheral vasodilator. When applied topically, minoxidil has been shown to stimulate hair growth in males and females with alopecia androgenetica; however, the exact mechanism of action of minoxidil in the treatment of alopecia androgenetica is not known. The regrowth can be observed after approximately 4 or more months of use and is variable among patients. Upon discontinuation of treatment with minoxidil, new hair growth stops and restoration of pretreatment appearance may occur within 3-4 months.

It is indicated in the treatment (regrowth) of androgenic alopecia in males and females and stabilization of hair loss in patients with androgenic alopecia.

A total dose of 1mL minoxidil should be applied twice per day to the scalp, beginning at the centre of the affected area. This dose should be used regardless of the size of the affected area. The total daily dose should not exceed 2mL. At least four months of twice daily applications of minoxidil are generally required before evidence of hair regrowth can be expected. Onset and degree may be variable among patients.

In general minoxidil is well tolerated. Most frequently reported adverse reactions with 2% and 5% topical minoxidil in are dermatological reactions and include: local erythema, itching, and dry skin/scalp flaking, skin irritation, rash, and dermatitis.

Before starting on minoxidil the patient should have a healthy, normal scalp. Patients with known cardiovascular disease or cardiac arrhythmias should contact a physician before using minoxidil. Minoxidil is recommended for use only in healthy adults with normal cardiovascular status.

Topical minoxidil is contraindicated in patients with a history of hypersensitivity to minoxidil or any of the components of the preparation.

There are no adequate and well-controlled studies in pregnant women. Minoxidil should be used during pregnancy only if the potential benefit justifies the risk to the fetus. Minoxidil should not be used by nursing women.

Xenogrow topical solution: Each bottle contains 60 ml of Minoxidil 2% and 5% topical solution.